Bronchopulmonary dysplasia (BPD) is described in the MONDO ontology as a chronic respiratory disease that results from complications related to lung injury during the treatment of infant acute respiratory distress syndrome in low-birth-weight premature infants, or from abnormal lung development in older infants. No genes are listed for this condition in this packet, and age-of-onset categories are not certified. The packet lists a prevalence category of common, corresponding to approximately 1 to 5 per 10,000 people.

According to the MONDO definition, clinical signs are tachypnea, tachycardia, and signs of respiratory distress such as intercostal recession, grunting, and nasal flaring. A structured phenotype list with frequency information is not certified in this packet, and experiences vary between individuals.

The MONDO definition attributes the condition to complications of lung injury during the treatment of infant acute respiratory distress syndrome in low-birth-weight premature infants, or to abnormal lung development in older infants. No causative genes are listed in this packet and no inheritance pattern is certified, so this description does not establish a genetic cause.

Diagnostic tests and criteria for this condition are not certified in this packet. The clinical signs in the MONDO definition describe presentation but are not presented as a diagnostic standard.

No FDA-approved treatments and no foundational therapies are certified in this packet. The packet lists FDA orphan drug designations for several investigational products, with indications described as prevention or treatment of bronchopulmonary dysplasia in premature infants or neonates; these include mesenchymal stem cell-based products, recombinant surfactant protein D products, vitamin A palmitate products, and lucinactant. An orphan drug designation is not an approval and does not establish that a product is effective. Other management approaches are not certified in this packet.

Prognosis is not certified in this packet, which provides no natural history information for this condition.

According to ClinicalTrials.gov records summarized in the packet, active clinical trials are listed for this condition. An example is NCT06897839, a Phase 2 trial titled "Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)", sponsored by Airway Therapeutics, Inc., recruiting, with dates from 2025-02-03 to 2030-04-30. A trial title does not establish that an intervention is beneficial. The full list is available through the ClinicalTrials.gov search link in the packet. No registries or patient organizations are listed in this packet.